Did you know?
ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.
Free Newsletter
Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!
Free Report
3SBio Inc. (沈阳三生制药) in-licensed the China...
3SBio Inc. (沈阳三生制药) has formed a strategic...
3SBio (沈阳三生制药) and Ascentage Pharma will...
3SBio Inc. in-licensed the China rights to voclosporin, a...
Golden Meditech raised $40 million in private equity for...
3SBio Inc. acquired worldwide rights to a clinical-stage...
China is expected to announce a $1.5 trillion, five-year...
3SBio Inc. was granted SFDA manufacturing approval of an...
3SBio reported the SFDA has approved its high-dose...
Novartis may IPO on the Shanghai stock exchange, which...
ChinaBio® News
Greg Scott Interviewed at BIO-Europe Spring
How to bring your China assets to China in 8 minutes
"Mr. Bio in China."
Mendelspod Interview
Multinational pharma held to a higher standard in China
